Relmada Therapeutics, Inc. (RLMD) Covered Calls

You can sell covered calls on Relmada Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RLMD (prices last updated Mon 10:50 AM ET):

Relmada Therapeutics, Inc. (RLMD) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
5.31 +0.06 5.29 5.31 90K - 0.2
Covered Calls For Relmada Therapeutics, Inc. (RLMD)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 16 5 1.40 3.91 27.9% 536%
Jan 20 5 1.70 3.61 38.5% 260%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.